-

Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 11:40 a.m. (ET).

The live webcast of the presentation can be accessed via the Investors section of our website, www.thermofisher.com.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Sandy Pound
Thermo Fisher Scientific
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com

Investor:
Rafael Tejada
Thermo Fisher Scientific
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:
Sandy Pound
Thermo Fisher Scientific
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com

Investor:
Rafael Tejada
Thermo Fisher Scientific
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

More News From Thermo Fisher Scientific Inc.

Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific’s Accelerator™ Drug Development 360° CDMO and CRO Solutions

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the findings of new research by the Tufts Center for the Study of Drug Development (CSDD) demonstrating the benefits of the company’s Accelerator™ Drug Development 360° CDMO and CRO solutions in helping biotech and biopharma companies speed life-changing medicines to patients.1 The findings show Thermo Fisher’s integrated services can potentially reduce drug development timelines...

Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples

UPPSALA, Sweden--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Regeneron Genetics Center® (RGC™) has selected the Olink Explore HT proteomics platform for a large-scale proteomics investigation involving nearly 200,000 patient samples from the Geisinger Health Study that aims to unlock new insights into the dynamic biology and mechanisms of human disease. The Geisinger Health Study, characterized by deep phenotyping data, offers a uniqu...

Thermo Fisher Scientific Unveils Next-generation Mass Spectrometers at ASMS 2025 to Revolutionize Biopharma Applications and Omics Research

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer (MS) and the Thermo Scientific™ Orbitrap™ Excedion™ Pro mass spectrometer (MS) to help push the boundaries of scientific discovery. Delivering unrivaled analytical performance and speed, the instruments are designed to uncover complex biological processes that could lead to advancements in p...
Back to Newsroom